Literature DB >> 17455115

Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model.

M L Jensen1, D Foster, R Upton, C Grant, A Martinez, A Somogyi.   

Abstract

The pharmacokinetics and time course of blood-brain equilibration of buprenorphine (BUP) and norbuprenorphine (norBUP) in sheep were characterized. Sheep were administered 0.04 mg kg(-1) BUP or 0.6 mg kg(-1) norBUP as 4-min i.v. infusions. The cerebral kinetics were inferred from arterio-sagittal sinus concentration gradients and changes in cerebral blood flow. These data were fitted to physiologically based pharmacokinetic models. BUP cerebral kinetics were best described by a membrane-limited model with a large equilibration delay (half-life of 20 min) between brain and blood due to intermediate permeability (47 ml min(-1)) and a large cerebral distribution volume (595 ml). Significant limitation in permeability (6 ml min(-1)) characterized the cerebral kinetics of norBUP with a cerebral distribution volume (157 ml) giving a blood-brain equilibration half-life (21 min) similar to that for BUP. The logD of BUP and norBUP were 3.93 +/- 0.08 and 1.18 +/- 0.04 (mean +/- SD), respectively. Both compounds revealed slow cerebral equilibration with variations in degree of permeability and distribution volume reflecting the difference in lipophilicity. It is possible that norBUP contributes to the central effects seen after chronic BUP administration as this study demonstrated its entry into the brain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17455115     DOI: 10.1080/00498250701251126

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

Review 1.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

2.  Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.

Authors:  Janet K Coller; Jennifer R Michalakas; Heather M James; Aaron L Farquharson; Joel Colvill; Jason M White; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

3.  Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose.

Authors:  Peter Athanasos; Walter Ling; Felix Bochner; Jason M White; Andrew A Somogyi
Journal:  Pain Med       Date:  2019-01-01       Impact factor: 3.750

4.  Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

Authors:  Sarah M Brown; Michael Holtzman; Thomas Kim; Evan D Kharasch
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

5.  Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide.

Authors:  Jinda Fan; Sarah M Brown; Zhude Tu; Evan D Kharasch
Journal:  Bioconjug Chem       Date:  2011-03-24       Impact factor: 4.774

6.  Limited Impact of Murine Placental MDR1 on Fetal Exposure of Certain Drugs Explained by Bypass Transfer Between Adjacent Syncytiotrophoblast Layers.

Authors:  Arimi Fujita; Saki Noguchi; Rika Hamada; Satoko Inoue; Tsutomu Shimada; Satomi Katakura; Tetsuo Maruyama; Yoshimichi Sai; Tomohiro Nishimura; Masatoshi Tomi
Journal:  Pharm Res       Date:  2022-01-26       Impact factor: 4.580

7.  A sensitive, simple and rapid HPLC-MS/MS method for simultaneous quantification of buprenorpine and its N-dealkylated metabolite norbuprenorphine in human plasma.

Authors:  Yi-Ya Wang; Xiao-Hang Shen; Hao Li; Feng-Ju Chen; Yan Fu; Li Ding
Journal:  J Pharm Anal       Date:  2013-01-04

Review 8.  Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection.

Authors:  Henriikka Hakomäki; Hannu Kokki; Marko Lehtonen; Veli-Pekka Ranta; Juha Räsänen; Hanna-Marja Voipio; Merja Kokki
Journal:  Pharmacol Res Perspect       Date:  2021-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.